Baseline characteristics of patients diagnosed with nonmelanoma skin cancer
| Baseline characteristics . | All cases (N = 90) . |
|---|---|
| Age, median (IQR), y (N = 90) | 73 (68-78) |
| Diagnosis | Myelofibrosis: 71/90 (78.9%) Polycythemia vera: 17/90 (18.9%) Essential thrombocythemia/polycythemia vera: 1/90 (1.1%) Other: 1/90 (1.1%) |
| DIPSS | Low: 2/58 (3.4%) Int-1: 6/58 (10.3%) Int-2: 42/58 (72.4%) High: 8/58 (13.8%) Not known: 13/61 Not applicable (nonmyelofibrosis cases): 19/90 |
| No. of prior therapies Not known: 3/90 | 0: 21/87 (24.1%) 1: 43/87 (49.4%) 2: 21/87 (24.1%) 3: 2/87 (2.3%) |
| Prior hydroxycarbamide use Not known: 2/90 | Yes: 60/88 (68.2%) No: 28/88 (31.8%) |
| History of skin cancer Not known: 3/90 Type of prior skin cancer Same cancer as history after ruxolitinib | Yes: 33/87 (37.9%) No: 54/87 (62.1%) |
| Squamous cell carcinoma: 12/33 (36.4%) Basal cell carcinoma: 7/33 (21.2%) Bowen disease: 3/33 (10%) Malignant melanoma: 1/33 (3%) >1 Type of skin cancer: 10/33 (30.3%) | |
| Yes: 15/23 No: 8/23 NA: 10/33 | |
| Additional immunosuppression Not known: 27/90 Types of additional immunosuppression | Yes: 19/63 (30.2%) No: 44/63 (69.8%) |
| Additional MPN treatment (6/19) Navitoclax: 2/19 Pelabresib: 1/19 Prior fedratinib: 1/19 Azacytidine: 2/19 Prior cancer/treatment (5/19) Prior CHOP for non-Hodgkin lymphoma: 1/19 Prior bendamustine and ofatumumab for chronic lymphocytic leukemia: 1/19 Prior allo-HCT and induction chemotherapy with daunorubicin and cytarabine: 1/19 Prior lobectomy for lung adenocarcinoma: 1/19 Prior immunotherapy for skin cancer: 1/19 Autoimmune and rheumatic disease/immunosuppression (5/19) Daily prednisolone: 2/19 Hydroxycarbamide for psoriasis: 1/19 Methotrexate for psoriasis: 1/19 Ulcerative colitis: 1/19 Other (3/19) Chronic kidney disease on hemodialysis: 1/19 Cardiac failure: 1/19 Prior ruxolitinib: 1/19 |
| Baseline characteristics . | All cases (N = 90) . |
|---|---|
| Age, median (IQR), y (N = 90) | 73 (68-78) |
| Diagnosis | Myelofibrosis: 71/90 (78.9%) Polycythemia vera: 17/90 (18.9%) Essential thrombocythemia/polycythemia vera: 1/90 (1.1%) Other: 1/90 (1.1%) |
| DIPSS | Low: 2/58 (3.4%) Int-1: 6/58 (10.3%) Int-2: 42/58 (72.4%) High: 8/58 (13.8%) Not known: 13/61 Not applicable (nonmyelofibrosis cases): 19/90 |
| No. of prior therapies Not known: 3/90 | 0: 21/87 (24.1%) 1: 43/87 (49.4%) 2: 21/87 (24.1%) 3: 2/87 (2.3%) |
| Prior hydroxycarbamide use Not known: 2/90 | Yes: 60/88 (68.2%) No: 28/88 (31.8%) |
| History of skin cancer Not known: 3/90 Type of prior skin cancer Same cancer as history after ruxolitinib | Yes: 33/87 (37.9%) No: 54/87 (62.1%) |
| Squamous cell carcinoma: 12/33 (36.4%) Basal cell carcinoma: 7/33 (21.2%) Bowen disease: 3/33 (10%) Malignant melanoma: 1/33 (3%) >1 Type of skin cancer: 10/33 (30.3%) | |
| Yes: 15/23 No: 8/23 NA: 10/33 | |
| Additional immunosuppression Not known: 27/90 Types of additional immunosuppression | Yes: 19/63 (30.2%) No: 44/63 (69.8%) |
| Additional MPN treatment (6/19) Navitoclax: 2/19 Pelabresib: 1/19 Prior fedratinib: 1/19 Azacytidine: 2/19 Prior cancer/treatment (5/19) Prior CHOP for non-Hodgkin lymphoma: 1/19 Prior bendamustine and ofatumumab for chronic lymphocytic leukemia: 1/19 Prior allo-HCT and induction chemotherapy with daunorubicin and cytarabine: 1/19 Prior lobectomy for lung adenocarcinoma: 1/19 Prior immunotherapy for skin cancer: 1/19 Autoimmune and rheumatic disease/immunosuppression (5/19) Daily prednisolone: 2/19 Hydroxycarbamide for psoriasis: 1/19 Methotrexate for psoriasis: 1/19 Ulcerative colitis: 1/19 Other (3/19) Chronic kidney disease on hemodialysis: 1/19 Cardiac failure: 1/19 Prior ruxolitinib: 1/19 |
allo-HCT, allogeneic haematopoietic stem cell transplant; CHOP, cyclophosphamide, hydroxydaunorubicin, vincristine (Oncovin), prednisolone; DIPSS, Dynamic International Prognostic Scoring System; Int, intermediate; NA, not applicable.